TY - JOUR
T1 - Review of brachytherapy clinical trials
T2 - a cross-sectional analysis of ClinicalTrials.gov
AU - Chen, David
AU - Parsa, Rod
AU - Chauhan, Kabir
AU - Lukovic, Jelena
AU - Han, Kathy
AU - Taggar, Amandeep
AU - Raman, Srinivas
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Introduction: Characterizing the landscape of clinical trials including brachytherapy can provide an overview of the current status and research trends which may guide further areas of investigation. Method: We queried 449,849 clinical trials from the ClinicalTrials.gov registry using brachytherapy-related keywords from 1980 to 2023, yielding 245 multi-arm and 201 single-arm, brachytherapy trials. Multi-arm and single-arm brachytherapy trials were compared using 12 trial protocol elements. Results: The number of trials including brachytherapy has increased over time, with over 60% of trials registered in 2010 onwards. The majority of clinical trials were Phase 2 or 3, evaluated both safety and efficacy, and were funded by academic sponsors. The most common tumor sites evaluated in brachytherapy clinical trials include prostate, cervix, liver, endometrium, and breast. Conclusion: There remains continued interest in clinical trials including brachytherapy focused on evaluation of novel delivery systems, treatment planning, and new indications. More brachytherapy clinical trials are needed to define the optimal clinical utilization and advance prospective research in this field.
AB - Introduction: Characterizing the landscape of clinical trials including brachytherapy can provide an overview of the current status and research trends which may guide further areas of investigation. Method: We queried 449,849 clinical trials from the ClinicalTrials.gov registry using brachytherapy-related keywords from 1980 to 2023, yielding 245 multi-arm and 201 single-arm, brachytherapy trials. Multi-arm and single-arm brachytherapy trials were compared using 12 trial protocol elements. Results: The number of trials including brachytherapy has increased over time, with over 60% of trials registered in 2010 onwards. The majority of clinical trials were Phase 2 or 3, evaluated both safety and efficacy, and were funded by academic sponsors. The most common tumor sites evaluated in brachytherapy clinical trials include prostate, cervix, liver, endometrium, and breast. Conclusion: There remains continued interest in clinical trials including brachytherapy focused on evaluation of novel delivery systems, treatment planning, and new indications. More brachytherapy clinical trials are needed to define the optimal clinical utilization and advance prospective research in this field.
KW - Brachytherapy
KW - Clinical Trials as Topic
KW - Cross-Sectional Studies
KW - Female
KW - Humans
KW - Male
UR - http://www.scopus.com/inward/record.url?scp=85185109292&partnerID=8YFLogxK
U2 - 10.1186/s13014-024-02415-8
DO - 10.1186/s13014-024-02415-8
M3 - Article
C2 - 38351013
AN - SCOPUS:85185109292
SN - 1748-717X
VL - 19
SP - 22
JO - Radiation Oncology
JF - Radiation Oncology
IS - 1
M1 - 22
ER -